Breaking the “Black Box” in Bioprocessing - Takeaways - MDSpire
Feature

Breaking the “Black Box” in Bioprocessing

Why understanding titer analytics is key to faster, more reliable biologics and gene therapy development

  • May 14, 2026

  • 10 min

Share

  • 1

    Analytics are crucial for innovation in biopharma.

  • 2

    Ruizhi Wang emphasizes accessibility and integration of analytical tools.

  • 3

    Abselion focuses on semiconductor technology for measuring titer data.

  • 4

    Common misconceptions about titer analytics exist.

  • 5

    Development timelines are pressuring quality data generation.

  • 6

    Regulatory guidance is shifting towards transparency in analytics.

  • 7

    Amperion technology can adapt across various biopharma modalities.

  • 8

    Integration of analytics is essential for reducing inefficiencies.

Original Source(s)

Breaking the “Black Box” in Bioprocessing

  • May 14, 2026

Related Content

AI Discharge Summaries Show Low Harm Risk

Most reviewed summaries were rated as posing no harm risk, although omissions remained common.

Makary Resigns as FDA Commissioner Following Policy Disputes

Transition follows disputes over vaccine policy, food additive regulation, and flavored vaping product authorization

Uric Acid Stone Dissolution Peaked at pH 7.2

In vitro study found dissolution rates increased sharply above pH 6.5 and were tenfold higher after stone fragmentation.